Scholarlink

<p><i>eIF6</i> is overexpressed in multiple cancers. Previous work has showed that deficiency alters the gut microbiota. This study investigated the mechanism linking <i>eIF6</i> deficiency, microbial dysbiosis, and colorectal cancer (CRC). <i>eIF6</i> expression was assessed in human and mouse CRC samples. Functional assays were conducted in mice with AOM/DSS-induced CRC. Antibiotic treatment and faecal microbiota transplantation (FMT) were applied to evaluate microbiota-mediated effects. 16S rDNA sequencing and <i>Dubosiella newyorkensis</i> (<i>D. newyorkensis</i>) supplementation were used to identify key bacteria. Metabolites from the bacterial supernatant were analysed via targeted mass spectrometry. The effect of indole-3-carboxaldehyde (3-ICA) was tested in murine models. <i>eIF6</i> expression was upregulated in CRC. Its deficiency reduced the tumour incidence and proliferation of tumours in mice and increased the abundance of beneficial bacteria such as <i>Akkermansia</i> and <i>Dubosiella</i>. FMT from e<i>IF6</i> deficient mice and <i>D. newyorkensis</i> administration attenuated tumorigenesis and enhanced barrier function. 3-ICA, a metabolite of <i>D. newyorkensis</i>, also suppressed CRC progression. <i>eIF6</i> deficiency exerts protective effects against CRC through the enrichment of <i>D. newyorkensis</i> and its metabolite 3-ICA, revealing a novel mechanism and potential therapeutic strategy for CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

eIF6 deficiency alleviates colorectal cancer by modulating the gut microbiota and related metabolites

  • 期刊论文

  • 发表日期：

    2026年1月31日

查看全文
  • Shuai Yang,
  • Jiawei Song,
  • Zhenzhen Wang,
  • Guang Peng,
  • Linglin Tong,
  • Xin Li,
  • Kexin Yang,
  • Yang Chen,
  • He Zhang,
  • Qing Zhang,
  • Renjin Chen

摘要

eIF6 is overexpressed in multiple cancers. Previous work has showed that deficiency alters the gut microbiota. This study investigated the mechanism linking eIF6 deficiency, microbial dysbiosis, and colorectal cancer (CRC). eIF6 expression was assessed in human and mouse CRC samples. Functional assays were conducted in mice with AOM/DSS-induced CRC. Antibiotic treatment and faecal microbiota transplantation (FMT) were applied to evaluate microbiota-mediated effects. 16S rDNA sequencing and Dubosiella newyorkensis (D. newyorkensis) supplementation were used to identify key bacteria. Metabolites from the bacterial supernatant were analysed via targeted mass spectrometry. The effect of indole-3-carboxaldehyde (3-ICA) was tested in murine models. eIF6 expression was upregulated in CRC. Its deficiency reduced the tumour incidence and proliferation of tumours in mice and increased the abundance of beneficial bacteria such as Akkermansia and Dubosiella. FMT from eIF6 deficient mice and D. newyorkensis administration attenuated tumorigenesis and enhanced barrier function. 3-ICA, a metabolite of D. newyorkensis, also suppressed CRC progression. eIF6 deficiency exerts protective effects against CRC through the enrichment of D. newyorkensis and its metabolite 3-ICA, revealing a novel mechanism and potential therapeutic strategy for CRC.